COST-EFFECTIVENESS AND BUDGET IMPACT ANALYSIS OF UPADACITINIB FOR THE TREATMENT OF MODERATE-TO-SEVERE ACTIVE CROHN'S DISEASE IN GREECE

被引：0
|
作者：
Vellopoulou, K. [1 ]
Lioliou, K. [1 ]
Papantoniou, P. [2 ]
Kotsis, I [2 ]
机构：
[1] Econcare LP, Athens, Greece
[2] AbbVie Hellas, Athens, Greece
来源：
VALUE IN HEALTH | 2024年 / 27卷 / 12期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
EE94
引用
收藏
页码：S72 / S72
页数：1
相关论文
共 50 条
  • [21] COST-EFFECTIVENESS OF SECUKINUMAB COMPARED WITH USTEKINUMAB AND ETANERCEPT FOR THE TREATMENT OF MODERATE-TO-SEVERE PLAQUE PSORIASIS IN GREECE
    Tzanetakos, C.
    Kourlaba, G.
    Chatzikou, M.
    Antoniou, C.
    Ioannidis, D.
    Lefaki, I
    Petridis, A.
    Rigopoulos, D.
    Roussaki-Schulze, A.
    Sotiriadis, D.
    Maniadakis, N.
    VALUE IN HEALTH, 2016, 19 (07) : A569 - A569
  • [22] Cost-effectiveness of secukinumab compared with ustekinumab and etanercept for the treatment of moderate-to-severe plaque psoriasis in Greece
    Tzanetakos, C.
    Kourlaba, G.
    Hatzikou, M.
    Antoniou, C.
    Ioannides, D.
    Lefaki, I.
    Petridis, A.
    Rigopoulos, D.
    Roussaki-Schulze, V.
    Sotiriadis, D.
    Maniadakis, N.
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2016, 30 : 61 - 62
  • [23] Cost-Effectiveness of Reimbursing Infliximab for Moderate to Severe Crohn's Disease in China
    Chen, Haotian
    Shi, Jihao
    Pan, Yipeng
    Zhang, Zhou
    Fang, Hao
    Chen, Ying
    Chen, Wendong
    Cao, Qian
    ADVANCES IN THERAPY, 2020, 37 (01) : 431 - 449
  • [24] Cost-Effectiveness of Reimbursing Infliximab for Moderate to Severe Crohn’s Disease in China
    Haotian Chen
    Jihao Shi
    Yipeng Pan
    Zhou Zhang
    Hao Fang
    Ying Chen
    Wendong Chen
    Qian Cao
    Advances in Therapy, 2020, 37 : 431 - 449
  • [25] COST-EFFECTIVENESS OF APREMILAST FOR THE TREATMENT OF MODERATE TO SEVERE PSORIASIS IN GREECE
    Solakidi, A.
    Tzanetakos, C.
    Maniadakis, N.
    VALUE IN HEALTH, 2017, 20 (09) : A803 - A803
  • [26] Cost-effectiveness analysis of amevivetm (Alefacept) in the treatment of patients with moderate-to-severe psoriasis
    Iskedjian, M
    Barkovsky, L
    Desjardins, O
    Walker, JH
    Dorkalam, M
    Shear, N
    Einarson, TR
    VALUE IN HEALTH, 2005, 8 (03) : 330 - 330
  • [27] THE COST-EFFECTIVENESS OF USTEKINUMAB IN MODERATE TO SEVERELY ACTIVE CROHN'S DISEASE IN SWEDEN
    Hansson-Hedblom, A.
    Almond, C.
    Borgstrom, F.
    Sly, I
    Enkusson, D.
    Buchholt, Troelsgaard A.
    Karlsson, L.
    VALUE IN HEALTH, 2017, 20 (09) : A634 - A634
  • [28] A new treatment for moderate-to-severe Crohn's disease
    Aschenbrenner, Diane S.
    AMERICAN JOURNAL OF NURSING, 2008, 108 (05) : 65 - 65
  • [29] The cost-effectiveness of ustekinumab for moderate-to-severe psoriasis
    Rouse, Nicole C.
    Farhangian, Michael E.
    Wehausen, Brooke
    Feldman, Steven R.
    EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2015, 15 (06) : 877 - 884
  • [30] Cost-Effectiveness Analysis of Triple Combination Preparations in the Treatment of Moderate-to-Severe Chronic Obstructive Pulmonary Disease
    Zhou, Yikang
    Long, Enwu
    Xu, Qian
    Wang, Lei
    Jiang, Xuehua
    Hu, Ming
    FRONTIERS IN PUBLIC HEALTH, 2021, 9
12345